

From: FL HIV-AIDS Patient Care Programs <FLHIV-AIDSPatientCarePrograms@flhealth.gov>

Sent: Tuesday, April 25, 2023 4:39 PM

Subject: Announcement: ADAP Formulary Update

Dear Colleagues,

We are pleased to announce an update to the AIDS Drug Assistance Program (ADAP) formulary May 1, 2023. These changes will improve the provision of quality treatment and allow ADAP clients to receive the latest medications.

Changes were implemented after review and consideration by the HIV Section Medication Formulary Workgroup, the Bureau of Public Health Pharmacy: Pharmacy and Therapeutics Committee, and the HIV/AIDS Section's administration.

The following medications are being added:

- Betamethasone/clotrimazole
- Ciprofloxacin/dexamethasone
- Dextromethorphan/promethazine
- Fluticasone/salmeterol
- Budesonide

Please direct any medical questions to Jeannette Iriye, RN, BSN, MSN, HIV/AIDS nurse consultant, at Jeannette.Iriye@flhealth.gov or 850-901-6708 or Dr. Andréa Sciberras, Medical Director, Division of Disease Control and Health Protection, at Andrea.Sciberras@flhealth.gov or (850) 756-2283.

If you have any questions or concerns regarding these formulary changes, contact the ADAP Central Office at 844-381-2327.

The complete ADAP formulary is available at FloridaADAP.org.

Kind regards,

Jimmy R. LLaque, Director
Florida HIV Patient Care and Treatment Access Program

Florida Department of Health | Division of Disease Control and Health Protection | Bureau of Communicable Diseases | HIV/AIDS Section
4052 Bald Cypress Way, Bin A-09, Tallahassee, FL 32399 | Office: 850.245.4477 | Mobile: 850.545.6836 | Fax: 850.412.2680

Florida Health, nationally accredited by the Public Health Accreditation Board, works to protect, promote and improve the health of all people in Florida through integrated state, county and community efforts.

NOTE: Florida has a very broad public records law. Most written communications to or from state officials regarding state business are public records available to the public and media upon request. Your email communication may therefore be subject to public disclosure.